Genetic (ERRα−/−) or pharmacological inhibition (synthetic inverse agonist C29) exacerbates rapamycin-induced NAFLD in mice [185] and impairs the reversal of fasting-induced NAFLD during refeeding [189]; activating ERRα appears more beneficial to treat and reverse the instilled disease. The gene discussed is ESRRA; the disease is metabolic dysfunction-associated steatotic liver disease.